| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥712.7B | ¥614.9B | +15.9% |
| Operating Income | ¥243.7B | ¥173.9B | +40.1% |
| Ordinary Income | ¥241.4B | ¥168.2B | +43.5% |
| Net Income | ¥172.5B | ¥122.9B | +40.3% |
| ROE | 10.9% | 8.1% | - |
FY2026 Q2 results: Revenue 712.7B yen (YoY +15.9%), Operating Income 243.7B yen (YoY +40.1%), Ordinary Income 241.4B yen (YoY +43.5%), Net Income 172.5B yen (YoY +40.3%). The company achieved strong profit growth exceeding revenue growth, driven by improved operating margins. Gross profit margin reached 70.6% with operating margin at 34.2%, reflecting a high value-added product mix primarily in the Medical segment. Basic EPS increased 43.0% to 64.56 yen, outpacing net income growth due to share buyback effects. Total assets grew modestly to 1,958.7B yen while equity strengthened to 1,586.7B yen, maintaining a robust equity ratio of 81.0%.
Revenue increased 97.8B yen YoY to 712.7B yen, representing 15.9% growth. The Medical segment generated 626.6B yen in external revenue (up 12.4% from prior period's 557.6B yen), while the Device segment contributed 169.2B yen (up 49.9% from prior period's 57.3B yen on internal sales basis). The Medical segment maintained its position as the core revenue driver with strong demand for catheter-based medical devices. Operating income surged 69.8B yen to 243.7B yen, with operating margin expanding 5.7 percentage points from 28.3% to 34.2%. This margin expansion was achieved through gross profit margin improvement to 70.6% (up from 66.4% estimated prior year) and SG&A ratio containment at 36.4% (down from 38.1% estimated prior year). Cost of sales increased only 39.0B yen against revenue growth of 97.8B yen, indicating favorable product mix and operational efficiency gains. SG&A expenses rose 35.1B yen but grew at a slower rate than revenue, contributing to operating leverage. Ordinary income of 241.4B yen versus operating income of 243.7B yen reflects net non-operating expenses of 2.3B yen, primarily consisting of FX losses of 3.2B yen partially offset by interest and dividend income of 1.5B yen. Non-operating items represent 0.3% of revenue, indicating minimal impact from financial activities. Extraordinary income of 6.3B yen from securities sales provided a non-recurring boost. The gap between ordinary income (241.4B yen) and net income (172.5B yen) of 68.9B yen is primarily attributable to income tax expense of 75.1B yen, representing an effective tax rate of 30.3%. This represents a revenue up, profit up pattern with strong operating leverage driving profit growth significantly above revenue growth.
Medical segment reported revenue of 626.6B yen and operating income of 239.5B yen, yielding an operating margin of 38.2%. This segment represents 87.9% of total external revenue and is clearly the core business. Operating income grew 29.3% from 185.2B yen in the prior period, demonstrating strong profit expansion. Device segment recorded revenue of 169.2B yen and operating income of 43.9B yen with a margin of 26.0%. On an external sales basis (86.0B yen), the Device segment serves both external customers and internal supply to Medical operations. Operating income increased 78.7% from 24.6B yen, reflecting improved capacity utilization and efficiency. The margin differential of 12.2 percentage points between Medical (38.2%) and Device (26.0%) reflects the higher value-added nature of finished medical devices versus component manufacturing. Both segments achieved double-digit profit growth, with Device showing stronger percentage gains off a smaller base.
[Profitability] ROE of 10.9% compares favorably to the prior period, driven by net profit margin expansion to 24.2% from 20.0% YoY. Operating margin of 34.2% improved 5.7 percentage points from 28.3%, reflecting strong pricing power and operational efficiency. Gross profit margin of 70.6% represents a high-value product portfolio with significant differentiation. [Cash Quality] Cash and deposits of 535.0B yen provide substantial liquidity, covering short-term liabilities 2.4 times over. Operating cash flow of 177.8B yen represents 1.03 times net income, confirming cash-backed earnings quality. However, cash conversion ratio of 0.62 (OCF to EBITDA) indicates working capital absorption. [Investment Efficiency] Asset turnover of 0.36 reflects capital-intensive manufacturing operations. Total assets of 1,958.7B yen include substantial property, plant and equipment of 608.8B yen. Inventory levels of 264.8B yen (finished goods 91.7B, work in process 102.0B, raw materials 71.1B) represent extended production cycles. [Financial Health] Equity ratio of 81.0% provides exceptional financial stability, well above typical manufacturing benchmarks. Current ratio of 467.6% and quick ratio of 426.6% indicate ample short-term liquidity. Long-term loans of 54.5B yen represent minimal leverage with net debt negligible against 535.0B yen cash position.
Operating cash flow of 177.8B yen represents 1.03 times net income of 172.5B yen, confirming solid cash-backed earnings. Cash flow from operations before working capital changes reached 230.7B yen, but was reduced by inventory increases of 12.1B yen, receivables increases of 3.9B yen, and payables decreases of 2.8B yen, reflecting working capital absorption of approximately 19B yen. Income taxes paid of 53.7B yen and interest paid of 0.8B yen were modest relative to profitability. Investing cash flow of negative 9.6B yen consisted primarily of capital expenditures of 23.7B yen, offset by investment securities transactions. Free cash flow of 168.3B yen (OCF plus investing CF) demonstrates strong cash generation capacity. Financing cash flow of negative 185.9B yen reflects significant capital allocation, with share repurchases of 105.5B yen representing the largest component, supplemented by dividend payments. Cash and deposits increased 20.1B yen YoY from 514.9B yen to 535.0B yen despite substantial shareholder returns, indicating robust underlying cash generation. The combination of strong operating cash flow and disciplined capital allocation supports continued shareholder returns while maintaining financial flexibility.
Ordinary income of 241.4B yen versus operating income of 243.7B yen shows net non-operating expenses of 2.3B yen, representing 0.3% of revenue and indicating minimal non-operating impact on core earnings. Non-operating income of 3.6B yen comprised interest income of 1.0B yen, dividend income of 0.5B yen, and other income of 0.8B yen. Non-operating expenses of 5.8B yen included interest expenses of 0.8B yen, foreign exchange losses of 3.2B yen, and other expenses of 1.9B yen. The FX losses reflect translation impacts on overseas operations and transactions. Extraordinary items totaled net gain of 6.2B yen, primarily from gain on sale of investment securities of 6.3B yen, representing a non-recurring boost to pre-tax income. Excluding this one-time gain, recurring pre-tax income would be approximately 241.4B yen. Operating cash flow of 177.8B yen compared to net income of 172.5B yen yields an OCF-to-net-income ratio of 1.03, indicating healthy cash conversion at the bottom line. However, comprehensive income of 243.8B yen exceeded net income by 71.4B yen due primarily to foreign currency translation adjustments of 69.4B yen, reflecting significant unrealized gains from overseas asset revaluation. Core recurring earnings quality remains strong with operating profits well-supported by cash generation, though working capital efficiency presents opportunity for improvement.
Full-year forecast projects revenue of 1,411.4B yen (YoY +17.6%), operating income of 422.2B yen (YoY +40.4%), and ordinary income of 426.9B yen (YoY +44.4%). First-half progress rates stand at 50.5% for revenue, 57.7% for operating income, and 56.5% for ordinary income, all exceeding the standard 50% benchmark for H1. Operating income progress of 57.7% suggests stronger first-half weighting, potentially due to product mix, customer order timing, or seasonal factors. The company revised its full-year forecast upward during the quarter, reflecting confidence in sustained demand and operational performance. EPS forecast of 114.88 yen for the full year implies second-half EPS of approximately 50.3 yen, down from first-half 64.56 yen, consistent with the lighter profit weighting expected in H2. The forecast assumes continued strength in the Medical segment with stable production and supply chain conditions. Given the ahead-of-schedule progress on profitability, the company appears well-positioned to meet or potentially exceed updated guidance, though second-half comparisons face tougher prior-year bases.
Annual dividend forecast is 46.10 yen per share, comprising an ordinary dividend of 40.31 yen and a commemorative dividend of 5.79 yen. This represents an increase from prior year levels, reflecting profit growth and cash generation capacity. Based on full-year EPS forecast of 114.88 yen, the payout ratio stands at 40.1%, within sustainable range below 60% threshold. The commemorative dividend recognizes a special milestone, adding 5.79 yen to the base dividend. Share buybacks executed during the period totaled 105.5B yen in cash outflows, representing substantial capital return to shareholders. Combined with projected annual dividends of approximately 122.4B yen (based on 265.3 million shares outstanding and 46.10 yen per share), total shareholder returns approach 228B yen. Against free cash flow of 168.3B yen for the half, the full-year total return ratio (dividends plus buybacks divided by net income) would exceed 70%, indicating highly aggressive capital return policy. Cash reserves of 535.0B yen and minimal debt provide sufficient cushion to support this distribution level, though sustainability depends on maintaining robust cash flow generation and working capital efficiency.
Product concentration risk in the Medical segment, which accounts for 87.9% of external revenue and 84.5% of segment operating income. Any disruption to demand for catheter-based devices, regulatory changes, or competitive pressures in this core business would materially impact consolidated results. Customer concentration within the Medical segment, while not quantified in available data, poses potential vulnerability if major hospital networks or distributors reduce purchases.
Working capital management risk, evidenced by inventory levels of 264.8B yen representing extended production and distribution cycles, combined with receivables of 166.5B yen. Prolonged working capital cycles absorb cash and reduce operational flexibility. Any deterioration in collection periods or inventory turnover would further pressure cash conversion efficiency, already reflected in cash conversion ratio of 0.62.
Foreign exchange exposure risk, with FX losses of 3.2B yen recorded in the current period and foreign currency translation adjustments of 69.4B yen in comprehensive income. The company's overseas operations and export activities create significant translation and transaction risk. Yen appreciation against major currencies would negatively impact both reported revenues from overseas subsidiaries and competitiveness of exports.
[Industry Position] (Reference - Proprietary Analysis)
Profitability: Operating margin 34.2% substantially exceeds manufacturing industry median of 8.8% (IQR: 3.0%-11.0%), positioning the company in the top tier for margin performance. Net profit margin of 24.2% compares very favorably to industry median of 5.4% (IQR: 1.1%-8.2%), reflecting a high-value specialized product portfolio. ROE of 10.9% outperforms industry median of 4.4% (IQR: 1.4%-8.7%), driven by superior profitability despite conservative leverage.
Financial Health: Equity ratio of 81.0% far exceeds industry median of 48.6% (IQR: 26.7%-65.2%), indicating exceptionally conservative capital structure. Current ratio of 467.6% substantially exceeds median of 2.74x (IQR: 2.27x-5.43x), reflecting very strong liquidity position and minimal financial risk.
Efficiency: Asset turnover of 0.36 aligns with industry median of 0.36 (IQR: 0.32-0.39), indicating typical capital intensity for the manufacturing sector. However, cash conversion ratio of 0.62 falls below industry median of 0.91 (IQR: -1.33-1.19), suggesting working capital management lags peers. Operating working capital turnover days would require further analysis but inventory levels appear elevated relative to efficiency benchmarks.
Growth: Revenue growth of 15.9% YoY exceeds industry median of 11.7% (IQR: -5.4%-28.3%), positioning the company in the stronger half of growth performers. EPS growth of 43.0% significantly outpaces industry median of 0.45 (IQR: -0.60-0.96), driven by margin expansion and share buyback effects.
The company demonstrates structural competitive advantages in profitability and financial strength versus manufacturing peers, offset by moderate efficiency challenges in working capital conversion that warrant management attention.
※ Industry: Manufacturing (7 companies), Comparison: Prior fiscal periods, Source: Proprietary analysis
Exceptional profitability structure with operating margin of 34.2% and net margin of 24.2% positions the company among industry leaders in value creation. The Medical segment's 38.2% operating margin reflects strong competitive moat through specialized catheter technology and customer relationships. This margin profile has expanded 5.7 percentage points YoY, suggesting ongoing product mix improvement and operating leverage as revenue scales. Sustainability of this margin premium depends on maintaining technological differentiation and managing competitive pressures in medical device markets.
Working capital efficiency presents material opportunity for cash flow enhancement, with current cash conversion ratio of 0.62 lagging both historical performance and industry benchmarks. Inventory of 264.8B yen and receivables of 166.5B yen represent substantial capital absorption relative to quarterly revenue of 712.7B yen annualized. Improvement in inventory turnover and collection cycles could release significant cash for additional shareholder returns or growth investment without compromising liquidity given 535.0B yen cash position.
Capital allocation strategy heavily prioritizes shareholder returns through aggressive buyback program of 105.5B yen in H1 alongside dividend increase to 46.10 yen. This return-focused approach is sustainable given robust cash generation and fortress balance sheet, but capital expenditure of 23.7B yen remains below depreciation of 44.6B yen, raising questions about long-term capacity and technology investment adequacy. The balance between immediate shareholder returns and reinvestment for sustained competitive position warrants monitoring, particularly as the Medical device industry requires ongoing R&D and manufacturing capability enhancement.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.